Recent Finacing
Recent Raise
Reverb Therapeutics' Amplify•R platform uses bispecific antibodies and modeling to redirect endogenous cytokines—IL-15 with PD‑1 blockade—to target tissues and reuse antibody modules across cancer and autoimmune programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
